CALCULATE YOUR SIP RETURNS

Wockhardt’s Shares Rise on Zaynich Achieves Breakthrough in Global Clinical Trials

Written by: Team Angel OneUpdated on: Jan 31, 2025, 4:26 PM IST
Wockhardt’s Zaynich has demonstrated groundbreaking efficacy in treating multidrug-resistant infections, achieving the highest success rates among FDA-approved antibiotics in the past decade.
Wockhardt’s Shares Rise on Zaynich Achieves Breakthrough in Global Clinical Trials
ShareShare on 1Share on 2Share on 3Share on 4Share on 5

Wockhardt Ltd’s flagship antibiotic, Zaynich, has demonstrated groundbreaking efficacy in a global Phase III clinical trial for complicated urinary tract infections. The drug has shown remarkable success in treating multidrug-resistant (MDR) and extensively drug-resistant (XDR) pathogens, positioning Wockhardt as a key player in the global pharmaceutical industry. Following this announcement, the company’s shares surged 10% on January 31, hitting the upper circuit on the BSE.

Exceptional Efficacy in Phase III Trials

The Enhance 1 Phase III study involved 530 patients across multiple regions, including the US, Europe, Latin America, China, and India. The study demonstrated a clinical cure rate of 96.8% for Zaynich at the test of cure, conducted 7-10 days after the final dose. Compared to the standard antibiotic meropenem, Zaynich exhibited superior efficacy, achieving a combined clinical and microbiologic cure rate of 89.0%, significantly higher than meropenem’s 68.4%.

This marks the highest-ever combined efficacy observed among FDA-approved antibiotics in the past decade. The drug specifically targets Gram-negative infections and has been developed over 14 years of research and development. Given the rising global concern over antibiotic resistance, this breakthrough represents a major advancement in treating severe infections.

Future Prospects and Global Impact

Zaynich’s effectiveness extends beyond complicated urinary tract infections, as it has demonstrated 97% clinical efficacy in trials involving meropenem-resistant infections such as hospital-acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VABP), bloodstream infections (BSI), and complicated intra-abdominal infections.

With these results, Wockhardt plans to file a New Drug Application (NDA) with the US FDA and a Marketing Authorisation Application (MAA) with the European Medicines Agency (EMA). The company’s success in developing a novel antibiotic for global markets establishes it as one of the few Indian pharmaceutical firms to make a significant impact in the field of antibiotic resistance.

Wockhardt Share Performance

As of January 31, 2025, at 1:38 PM, Wockhardt’s shares are locked in the upper circuit at ₹1,416.90 per share, up 10% from yesterday’s closing price.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Published on: Jan 31, 2025, 4:26 PM IST

Team Angel One

Team Angel One is a group of experienced financial writers that deliver insightful articles on the stock market, IPO, economy, personal finance, commodities and related categories.

Know More

We're Live on WhatsApp! Join our channel for market insights & updates

Open Free Demat Account!

Join our 3 Cr+ happy customers

+91
Enjoy Zero Brokerage on Equity Delivery
4.4 Cr+DOWNLOADS
Enjoy ₹0 Account Opening Charges

Get the link to download the App

Get it on Google PlayDownload on the App Store
Open Free Demat Account!
Join our 3 Cr+ happy customers